相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
Violetta V. Leshchenko et al.
BLOOD (2010)
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
Jian-Jun Zhao et al.
BLOOD (2010)
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Andrew C. Hsieh et al.
CANCER CELL (2010)
Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Veronica Fernandez et al.
CANCER RESEARCH (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis
Mei Liang et al.
MODERN PATHOLOGY (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling
Silvia Bea et al.
BLOOD (2009)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas
Keiichiro Honma et al.
BLOOD (2009)
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
Antonina V. Kurtova et al.
BLOOD (2009)
BAFF-R promotes cell proliferation and survival through interaction with IKKβ and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells
Lingchen Fu et al.
BLOOD (2009)
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma
Inga Vater et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
Lakshmi Srinivasan et al.
CELL (2009)
p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA
Elisabeth Hedstrom et al.
CELL CYCLE (2009)
Targeting mTOR globally in cancer Thinking beyond rapamycin
Boris Shor et al.
CELL CYCLE (2009)
Phosphatidylinositol 3′-Kinase Catalytic Subunit α Gene Amplification Contributes to the Pathogenesis of Mantle Cell Lymphoma
Amanda Psyrri et al.
CLINICAL CANCER RESEARCH (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Min H. Kang et al.
CLINICAL CANCER RESEARCH (2009)
Update on Hsp90 Inhibitors in Clinical Trial
Y. S. Kim et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Mantle Cell Lymphoma with Flow Cytometric Evidence of Clonal Plasmacytic Differentiation: A Case Report
Hina Naushad et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
Ana Mozos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Nuclear Cyclin D1: An Oncogenic Driver in Human Cancer
Jong Kyong Kim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Annina Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma
Robert S. Boyd et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
Proximal events in Wnt signal transduction
Stephane Angers et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells
A. Prasad et al.
ONCOGENE (2009)
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
Qiuyan Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Perifosine: Update on a Novel Akt Inhibitor
Joell J. Gills et al.
CURRENT ONCOLOGY REPORTS (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2008)
Therapeutic activity of mTOR inhibitors in mantle cell lymphoma - Clues but no clear answers
Anas Younes
AUTOPHAGY (2008)
Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma
Pascal Gelebart et al.
BLOOD (2008)
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Jessica Dal Col et al.
BLOOD (2008)
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma
Robert W. Chen et al.
BLOOD (2008)
Nuclear expression of the non-B-cell lineage Sox 11 transcription factor identifies mantle cell lymphoma
Sara Ek et al.
BLOOD (2008)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies
Luca Paoluzzi et al.
BLOOD (2008)
Mutations in Fbx4 inhibit dimerization of the SCFFbx4 ligase and contribute to cyclin D1 overexpression in human cancer
Olena Barbash et al.
CANCER CELL (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations
Sandrine Sander et al.
HAEMATOLOGICA (2008)
Elevated levels of oncogenic protein kinase pim-1 induce the p53 pathway in cultured cells and correlate with increased mdm2 in mantle cell lymphoma
Carol Hogan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
David T. Yang et al.
MOLECULAR CANCER (2008)
Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma
Ganapati V. Hegde et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Molecular genetic characterization reveals new subsets of mantle cell lymphoma
Emma Flordal Thelander et al.
LEUKEMIA & LYMPHOMA (2008)
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-κB pathways
Edgar Gil Rizzatti et al.
LEUKEMIA & LYMPHOMA (2008)
Signal transduction pathways of mantle cell lymphoma: A phosphoproteome-based study
Daniela Cecconi et al.
PROTEOMICS (2008)
Speeding through cell cycle roadblocks: Nuclear cyclin D1-dependent kinase and neoplastic transformation
Laura L Pontano et al.
Cell Division (2008)
Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference
Eva Ortega-Paino et al.
BLOOD (2008)
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
Norihiko Kawamata et al.
BLOOD (2007)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
Tint Lwin et al.
BLOOD (2007)
Essential role of stromally induced hedgehog signaling in B-cell malignancies
Christine Dierks et al.
NATURE MEDICINE (2007)
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis
Magda Pinyol et al.
BLOOD (2007)
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
Patricia Perez-Galan et al.
BLOOD (2007)
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
O. Weigert et al.
LEUKEMIA (2007)
The Bcl-2 apoptotic switch in cancer development and therapy
J. M. Adams et al.
ONCOGENE (2007)
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition
Silke Meister et al.
CANCER RESEARCH (2007)
Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level
Gael Roue et al.
JOURNAL OF IMMUNOLOGY (2007)
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T. Haritunians et al.
LEUKEMIA (2007)
Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309
Elena Hartmann et al.
HAEMATOLOGICA (2007)
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Cinta Mestre-Escorihuela et al.
BLOOD (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Adrian Wiestner et al.
BLOOD (2007)
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
Evangelia Peponi et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Mining the Wnt pathway for cancer therapeutics
Nick Barker et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
Jens R. Sydor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9
Georgios V. Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins
D. Zhai et al.
CELL DEATH AND DIFFERENTIATION (2006)
Mantle cell lymphoma with plasma cell differentiation
Ken H. Young et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
Lingchen Fu et al.
BLOOD (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival
S Ek et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
A Rinaldi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma
G Hutter et al.
GENES CHROMOSOMES & CANCER (2006)
Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma
AB Gladden et al.
ONCOGENE (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
Michal Marzec et al.
BLOOD (2006)
Life in the balance: how BH3-only proteins induce apoptosis
SN Willis et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Pathogenesis of mantle-cell lymphoma:: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
V Fernàdez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma
S Shishodia et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways
EG Rizzatti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Expression of the NF-κB targets BCL2 and BIRCS/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively
L Tracey et al.
JOURNAL OF PATHOLOGY (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function
L Chen et al.
MOLECULAR CELL (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Hedgehog signalling in cancer formation and maintenance
MP di Magliano et al.
NATURE REVIEWS CANCER (2003)
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma:: correlation with genomic aberrations, clinical characteristics, and outcome
D Kienle et al.
BLOOD (2003)
Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis
LV Pham et al.
JOURNAL OF IMMUNOLOGY (2003)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
J Orchard et al.
BLOOD (2003)
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
SH Walsh et al.
BLOOD (2003)
Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations
FI Camacho et al.
BLOOD (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression
JD Khoury et al.
JOURNAL OF PATHOLOGY (2003)
NF-kappa B at the crossroads of life and death
M Karin et al.
NATURE IMMUNOLOGY (2002)
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances
E Camacho et al.
BLOOD (2002)
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray
WK Hofmann et al.
BLOOD (2001)
分享论文
